Osivax
A company developing "universal" vaccines able to prevent highly-mutating respiratory viral infections . Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
CAD48—72m (Dealroom.co estimates Jul 2019.)
Company register number 829604750
Lyon Auvergne-Rhône-Alpes (HQ)
Financials
Estimates*
| EUR | 2017 | 2018 |
|---|---|---|
| Revenues | <1m | <1m |
| % growth | - | (38 %) |
| EBITDA | - | (1.9m) |
| % EBITDA margin | - | (2419 %) |
| Profit | (1.2m) | (1.7m) |
| % profit margin | (998 %) | (2212 %) |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | €2.7m | Seed |
* | €8.0m | Series A | |
€2.5m | Grant | ||
€15.0m | Grant | ||
€1.9m | Convertible | ||
€2.0m | Convertible | ||
* | €10.0m | Grant | |
* | $1.0m | Grant | |
* | $1.5m | Grant | |
| Total Funding | CAD66.5m | ||
Related Content
Recent News about Osivax
EditMore about Osivax
EditDeveloper of a universal vaccine designed to prevent globally impactful infectious diseases. The company's vaccine leverages its technology and acts as a universal vaccine against all existing and emerging coronavirus infections, preventing globally impactful infectious diseases, and enabling medical practitioners to treat patients with cancer as well as influenza, malaria, and other infectious diseases effectively.
Keywords: Pharmaceuticals and Biotechnology, Cancer Immunotherapy, Covid-19 Vaccines, Hpv Vaccines, Immunology, Infectious Disease, Influenza Vaccination, Vaccine Development Platform, Vaccines Candidate.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.